Page last updated: 2024-12-07
pyrrolidin-3-yl-methanesulfonic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 125605 |
| SCHEMBL ID | 20754591 |
| MeSH ID | M0127374 |
Synonyms (11)
| Synonym |
|---|
| pmsa |
| pyrrolidin-3-ylmethanesulfonamide |
| 95596-30-8 |
| 3-pyrrolidinemethanesulfonamide, 1,2,3,6-tetrahydro-, (+-)- |
| pyrrolidin-3-yl-methanesulfonic acid |
| 1-(pyrrolidin-3-yl)methanesulfonamide |
| DTXSID30914924 |
| JFINOWIINSTUNY-UHFFFAOYSA-N |
| SCHEMBL20754591 |
| EN300-702738 |
| (pyrrolidin-3-yl)methanesulfonamide |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " We report that, at high concentrations (300 microM-30 mM), a folic acid hexaglutamate analog is dose-dependently toxic to dissociated rat cortical cultures and that this toxicity is reversed by 2-PMPA, a potent and selective NAALADase inhibitor." | ( Toxicity induced by a polyglutamated folate analog is attenuated by NAALADase inhibition. Olkowski, JL; Slusher, BS; Thomas, AG; Vornov, JJ, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.62
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.62) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 3 (33.33%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (55.56%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||